Affirming the Practical Edge of T-Cell Engagers Over CAR-Ts in Autoimmune Indications
Time: 9:30 am
day: Day One
Details:
- Highlighting how T-cell engagers eliminate the time, complexity, and infrastructure burden of autologous CAR-T therapies, offering a plug-and-play treatment modality that’s immediately available at the bedside
- Unpacking the operational and clinical risks of CAR-T (e.g. ICU admissions, lymphodepletion, secondary malignancy risk) and contrasting them with the more controlled, predictable, and scalable safety profile of TCEs
- Discussing why the economic and logistical footprint of CAR-T is poorly suited to large autoimmune populations, and how TCEs unlock the potential for broader patient access without compromising potency
